News

New Study Shows How Providers Can Use Apretude To Prevent And Treat HIV In Black Women
A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) ...
The Washington Informer2h
Whitman-Walker Celebrates PrEP Awareness Day; Health Provider Offers Resources, Education, Call to Action
Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...
BioSpace14h
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...
Managed Healthcare Executive7h
The HIV Prevention Pipeline | IAS 2025
Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...
Managed Healthcare Executive15h
Study Participants Happy They Switched from Oral PrEP to Long-Acting Injections
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
Clinical Trials Arena on MSN17h
MSD progresses once-monthly HIV PrEP into Phase III
Announced at the International AIDS Society (IAS) 2025 conference taking place from 13-17 July in Kigali, Rwanda, MSD has launched two Phase III trials, EXPrESSIVE-10 and EXPrESSIVE-11, which will ...
Zacks Investment Research on MSN11h
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...